Incyte Japan Urges Reward for Innovation in Rare Diseases as Pemazyre Filed for Ultra Orphan Cancer

Shoji Kuroyama, Executive Director, Head of Product and Commercial Strategy (left), and Kazumi Suzukawa, Senior Medical Director, Clinical Development, Incyte Biosciences Japan Last year, Incyte scored its first stand-alone launch in Japan with Pemazyre (pemigatinib) for the treatment of biliary...read more